SCHEMBL4334964

SCHEMBL4334964

O=C(NC[C@H]1CCCO1)c1cc2c(-c3cc4ccccc4s3)n[nH]c2cc1F

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.48
NPC1 O15118 4/20 0.48
GSK3B P49841 2/20 0.47
MAPK10 P53779 1/20 0.47
KCNH2 Q12809 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ALDH1A1 P00352 6/20 0.47
KDM4E B2RXH2 5/20 0.47
HPGD P15428 2/20 0.47
HSD17B10 Q99714 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SIRT2 Q8IXJ6 1/20 0.43
SIRT1 Q96EB6 1/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 2/20 0.43
GAA P10253 1/20 0.43
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4339880 1.00 RAB9A (0.48) RAB9ANPC1GSK3BMAPK10KCNH2
SCHEMBL4338881 0.88 KDM4E (0.53) RAB9ANPC1MAPK10SMN1; SMN2ALDH1A1
SCHEMBL4338646 0.85 GSK3B (0.54) RAB9ANPC1GSK3BKCNH2SMN1; SMN2
SCHEMBL4336801 0.85 GSK3B (0.54) RAB9ANPC1GSK3BKCNH2SMN1; SMN2
SCHEMBL2862938 0.81 MAPK10 (0.50) RAB9ANPC1MAPK10KCNH2L3MBTL1
SCHEMBL4343378 0.80 KMT2A (0.47) RAB9ANPC1SMN1; SMN2ALDH1A1KDM4E
SCHEMBL4334072 0.78 HPGD (0.47) RAB9ANPC1MAPK10SMN1; SMN2ALDH1A1
SCHEMBL13635773 0.77 MAPK10 (0.48) NPC1GSK3BMAPK10ALDH1A1KDM4E
SCHEMBL4341432 0.77 ALDH1A1 (0.47) MAPK10SMN1; SMN2ALDH1A1KDM4EHPGD
SCHEMBL2862999 0.77 MAPK10 (0.47) MAPK10SIRT2SIRT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-7776890-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2010-08-17 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-20090203691-A1 Novel 1H-indazole compounds OINUMA HITOSHI 2009-08-13 US disclosed
US-7541376-B2 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2009-06-02 US disclosed
US-20050282880-A1 Novel 1H-indazole compounds EISAI R&D MANAGEMENT CO., LTD. (JP) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203691-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 RAB9A 2355/4885NPC1 1164/4885GSK3B 991/4885
US-20050282880-A1 Novel 1H-indazole compounds MAPK1, MAPK3, MAPK13 RAB9A 2355/4885NPC1 1164/4885GSK3B 991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.